Price T Rowe Associates Inc. MD lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 12.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,642,801 shares of the medical equipment provider’s stock after acquiring an additional 1,215,935 shares during the quarter. Price T Rowe Associates Inc. MD owned 0.05% of Zimmer Biomet worth $1,404,638,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in ZBH. Magnetar Financial LLC increased its holdings in Zimmer Biomet by 11.9% in the first quarter. Magnetar Financial LLC now owns 825,449 shares of the medical equipment provider’s stock valued at $108,943,000 after buying an additional 87,729 shares in the last quarter. LRI Investments LLC purchased a new position in Zimmer Biomet in the first quarter valued at about $68,000. 1832 Asset Management L.P. increased its holdings in Zimmer Biomet by 2.0% in the first quarter. 1832 Asset Management L.P. now owns 14,016 shares of the medical equipment provider’s stock valued at $1,850,000 after buying an additional 275 shares in the last quarter. Toronto Dominion Bank increased its holdings in Zimmer Biomet by 2.1% in the first quarter. Toronto Dominion Bank now owns 121,004 shares of the medical equipment provider’s stock valued at $15,970,000 after buying an additional 2,456 shares in the last quarter. Finally, EP Wealth Advisors LLC purchased a new position in shares of Zimmer Biomet during the 1st quarter worth approximately $282,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.
Zimmer Biomet Trading Up 0.6 %
Shares of ZBH traded up $0.65 during mid-day trading on Friday, reaching $111.29. The company had a trading volume of 1,399,353 shares, compared to its average volume of 1,448,416. The stock has a market cap of $22.90 billion, a price-to-earnings ratio of 24.09, a price-to-earnings-growth ratio of 2.00 and a beta of 1.01. The firm has a fifty day simple moving average of $110.44 and a 200-day simple moving average of $119.53. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $142.54. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38.
Zimmer Biomet Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.86%. Zimmer Biomet’s payout ratio is 20.78%.
Wall Street Analysts Forecast Growth
ZBH has been the subject of a number of recent research reports. Morgan Stanley dropped their price objective on shares of Zimmer Biomet from $130.00 to $120.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. Barclays decreased their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research report on Friday, May 31st. Oppenheimer raised their target price on shares of Zimmer Biomet from $150.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Truist Financial decreased their target price on shares of Zimmer Biomet from $130.00 to $117.00 and set a “hold” rating on the stock in a research report on Tuesday, July 16th. Finally, Evercore ISI decreased their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 2nd. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $129.53.
Check Out Our Latest Stock Analysis on ZBH
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
Featured Stories
- Five stocks we like better than Zimmer Biomet
- How Can Investors Benefit From After-Hours Trading
- Is Crypto Cool Again? What Stocks You Should Be Watching
- There Are Different Types of Stock To Invest In
- Why Call Options Volume for These 2 Stocks Spiked Together
- Investing in Construction Stocks
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.